BioStem Technologies, Inc. (BSEM) News
Follow BioStem Technologies, Inc. (BSEM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
BioStem Reports Q3 Revenue of $7.6 Million, Raises 2026 Guidance
BioStem reported a GAAP net loss of $11.4 million for the quarter ended September 30, 2026. It raised full-year revenue guidance to $28 million–$29 million from $26 million–$29 million.
EQUITY | Nov 13, 2026, 02:07 PM UTC
M
BioStem Raises 2026 Revenue Outlook to $28M–$29M
BioStem reported Q3 2026 revenue of $7.6 million, down from $10.5 million a year earlier, and raised its 2026 revenue outlook to $28 million–$29 million from $26 million–$29 million. Cash was $1.0 million at quarter-end;
EARNINGS | Nov 12, 2026, 09:13 PM UTC
L
BioStem Technologies Inc. (BSEM) Prices $3M Private Placement With Warrants
BioStem Technologies priced a ~$3M private placement of 735,296 shares at $4.08 with Series A and B warrants (exercise $3.83). Warrants are immediately exercisable; A expire 5 years after resale registration effectivenes
EQUITY | Sep 30, 2026, 12:09 PM UTC
L
BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. NASDAQ:BSEM (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercia
NEWS | Sep 30, 2026, 12:08 PM UTC
L
BSEM - Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform
BSEM - Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform
NEWS | Sep 21, 2026, 08:30 PM UTC
M
BioStem Technologies gets up to $40M committed equity facility
BioStem Technologies said it entered a committed equity facility for up to $40 million.
EQUITY | Sep 18, 2026, 11:02 AM UTC
L
BSEM - BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
BSEM - BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
NEWS | Sep 18, 2026, 11:00 AM UTC
L
BioStem adds hospital access for VENDAJE products via Vizient and Premier
BioStem Technologies said additions extend its hospital channel to its BioRetain wound care line, opening hospital access for VENDAJE® and VENDAJE AC® through Vizient and Premier.
EQUITY | Sep 04, 2026, 11:07 AM UTC
L
BioStem Technologies opens hospital access for VENDAJE® via Vizient and Premier
BioStem Technologies says it has opened hospital access for VENDAJE® and VENDAJE AC® through Vizient and Premier.
EQUITY | Sep 04, 2026, 11:00 AM UTC
L
BioStem Technologies to present at H.C. Wainwright global investment conference
BioStem Technologies Inc. (BSEM) said it will present at the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 03, 2026, 08:07 PM UTC
L
BioStem Technologies to present at H.C. Wainwright conference
BioStem Technologies says it will present at the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 03, 2026, 08:06 PM UTC
L
BSEM - BioStem Technologies to Present at the Sidoti MicroCap Conference
BSEM - BioStem Technologies to Present at the Sidoti MicroCap Conference
EQUITY | Aug 14, 2026, 08:05 PM UTC
L
BSEM Reports Q2 2026 Financial Results
BioStem Technologies reports second quarter 2026 financial results
EARNINGS | Aug 12, 2026, 08:08 PM UTC
L
BioStem files registration statement with SEC, to pursue Nasdaq listing
BioStem Technologies announced the filing of a Form 10 registration statement with the SEC to register its shares of common stock pursuant to the Securities Exchange Act of 1934, as amended, and reaffirmed its strategic
EQUITY | Jul 10, 2026, 11:07 AM UTC